Novo Nordisk A/S (NYSE:NVO) Trading 1.2% Higher – Time to Buy?

Novo Nordisk A/S (NYSE:NVO) shares shot up 1.2% on Thursday . The stock traded as high as $36.98 and last traded at $36.9220. 14,564,570 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 24,040,957 shares. The stock had previously closed at $36.48.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi?month subscription program for Wegovy to lower out?of?pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self?pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross?trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP?1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug?pricing body for heart?disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium?term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once?a?week insulin work and early triple?agonist studies — supports longer?term growth optionality beyond current GLP?1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP?1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low?cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re?pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near?term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Citigroup assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Down 0.2%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company’s 50-day moving average price is $43.43 and its 200 day moving average price is $49.85. The stock has a market capitalization of $164.86 billion, a P/E ratio of 10.64, a P/E/G ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 50.43%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. grew its stake in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares in the last quarter. Capital International Investors boosted its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Boston Partners bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $310,199,000. Price T Rowe Associates Inc. MD grew its position in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC grew its position in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after purchasing an additional 4,302,126 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.